Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women

Fertility and Sterility

Volumn 82, Issue 3, 2004, Pages 634-638

  Christodoulakos, George ^a,b   Lambrinoudaki, Irene ^a   Panoulis, Constantinos ^a   Papadias, Constantinos ^a   Economou, Emmanuel ^a   Creatsas, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Athens GR 10674 Greece ^*  (Greece)

Author keywords

estrogen; HT; raloxifene; VE cadherin

Indexed keywords

ESTRADIOL; NORETHISTERONE ACETATE; RALOXIFENE;

ADULT; ARTICLE; ATHEROMATOSIS; BLOOD VESSEL WALL; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HORMONAL THERAPY; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

ANTIGENS, CD; CADHERINS; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; RALOXIFENE;

EID: 4544349228     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2004.03.030     Document Type: Article

References (33)

1. N. Lopes, S.S. Vasudevans, R.J. Alvarez, P.F. Binkley, P.J. Goldschmidt Pathophysiology of plaque instability: insights at the genomic level Prog Cardiovasc Dis 44 2002 323 338
2. J.C. Stevenson Cardiovascular effects of estrogens J Steroid Biochem Mol Biol 74 2000 387 393
3. J.A. Epstein, D.J. Rader, M.S. Parmacek Perspective: cardiovascular disease in the postgenomic era - lessons learned and challenges ahead Endocrinology 143 2002 2045 2050
4. L. Robbie, P. Libby Inflammation and atherothrombosis Ann NY Acad Sci 947 2001 167 179
5. M. Cushman Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation Am J Cardiol 90 2002 7F 10F
6. D. Zanger, B.K. Yang, J. Ardans, M.A. Waclawiw, G. Csako, L.M Wahl Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management J Am Coll Cardiol 36 2000 1797 1802
7. The Writing Group for the Women's Health Initiative investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 288 2002 321 333
8. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B Riggs Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
9. Y.V. Bobryshev, S.M. Cherian, S.J. Inder, R.S.A. Lord Neovascular expression of VE-cadherin in human atherosclerotic arteries and its relation to intimal inflammation Cardiovasc Res 43 1999 1003 1017
10. J. Fujimoto, H. Sakaguchi, R. Hirose, T. Tamaya Sex steroidal regulation of vessel permeability associated with vessel endothelial cadherin (V-cadherin) J Steroid Biochem Mol Biol 67 1998 25 32
11. B. Herren, B. Levkau, E.W. Raines, R. Ross Cleavage of β-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role of caspases and metalloproteinases Mol Biol Cell 9 1998 1589 1601
12. J. Friedl, M. Puhlmann, D.L. Bartlett, S.K. Libutti, E.N. Turner, M.F Gnant Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF Blood 100 2002 1334 1339
13. S. Hofmann, H. Grasberger, P. Jung, M. Bidlingmaier, J. Vlotides, O.E Janssen The tumor necrosis factor-α induced vascular permeability is associated with the induction of VE-cadherin expression Eur J Med Res 7 2002 171 176
14. E.P. Moiseeva Adhesion receptors of vascular smooth muscle cells and their functions Cardiovasc Res 52 2001 372 386
15. P. Libby, P.M. Ridker, A. Maseri Inflammation and atherosclerosis Circulation 105 2002 1135 1143
16. N.T. Mulvihill, J.B. Folley Inflammation in acute coronary syndromes Heart 87 2002 201 204
17. T. Simoncini, S. Maffei, G. Basta, G. Barsacchi, A.R. Genazzani, J.K Liao Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms Circ Res 87 2000 19 25
18. J.A. Ardans, A. Blum, P.R. Mangan, S. Wientroub, R.O. Cannon 3rd, L.M. Wahl Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes Arterioscler Thromb Vasc Biol 21 2001 1265 1268
19. T. Nickelsen, G. Creatsas, T. Rechberger, H. Depypere, M. Erenus, D Quail Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study Climacteric 4 2001 320 331
20. B.W. Walsh, L.H. Kuller, R.A. Wild, S. Paul, M. Farmer, J Lawrence Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women JAMA 279 1998 1445 1451
21. B.W. Walsh, S. Paul, R.A. Wild, R.A. Dean, R.P. Tracy, D.A Cox The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial J Clin Endocrinol Metab 85 2000 214 218
22. G. Christodoulakos, I. Lambrinoudaki, C. Panoulis, D. Rizos, J. Coutoukos, G. Creatsas Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women Fertil Steril 79 2003 455 456
23. G.C. Creatsas, A.B. Malamitsi-Puchner, E.A. Hassan, E.B. Economou, D.I. Aravantinos Endothelin serum levels in primary amenorrheic adolescents before and after estrogen treatment J Soc Gynecol Invest 3 1996 350 353
24. G. Christodoulakos, C. Panoulis, E. Kouskouni, C. Chondros, S. Dendrinos, G. Creatsas Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis Gynecol Endocrinol 16 2002 9 17
25. R. Rahimian, I. Laher, G. Dube, C. van Breeman Estrogen and selective estrogen receptor modulator LY 117018 enhance release of nitric oxide in ref aorta J Pharmacol Exp Ther 283 1997 116 122
26. M.N. Bui, A.E. Arai, L. Hathaway, M.A. Waclawiw, G. Csako, R.O. Cannon 3rd Effect of hormone replacement therapy on carotid arterial compliance in healthy postmenopausal women Am J Cardiol 90 2002 82 85
27. N. Colacurci, D. Manzella, F. Fornaro, M. Carbonella, G. Paolisso Endothelial function and menopause: effects of raloxifene administration J Clin Endocrinol Metab 88 2003 2135 2140
28. M.L. Corcoran, R.E. Hewitt, D.E. Kleiner Jr, W.G. Stetler-Stevenson MMP-2: expression, activation and inhibition Enzyme Protein 49 1996 7 19
29. H.D. Intengan, E.L. Schiffrin Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis Hypertension 38 2001 581 587
30. Christodoulakos G, Panoulis C, Lambrinoudaki I, Botsis D, Dendrinos S, Economou E, et al. The effect of hormone replacement therapy and raloxifene on serum matrix metalloproteinases-2 and -9 in postmenopausal women. Menopause 2004;11:299-305.
31. P.K. Shah Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion Prog Cardiovasc Dis 44 2002 357 368
32. H. Nagase, J.F. Woessner Matrix metalloproteinases J Biol Chem 274 1999 21491 21494
33. Z.S. Galis, J.J. Khtzi Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad and the ugly Circ Res 90 2002 251 262